C3 Glomerulopathy

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Nester describes the evolving C3G therapeutic landscape, the value of now having pegcetacoplan to offer patients, and trial data supporting its approval.

In the final segment of this 5-part HCPLive RX Review, experts discuss real-world barriers to implementing new C3G therapies and lingering unmet needs.

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

Check out the latest renal regulatory news, clinical trial data, and nephrology research in this July 2025 recap.

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

C3G treatment options expand with FDA approvals of pegcetacoplan and iptacopan, offering new hope for patient care.

FDA approves pegcetacoplan (Empaveli) for treating C3 glomerulopathy and primary IC-MPGN, offering hope for patients aged 12 and older.

The Q2 recap for nephrology spotlights key FDA decisions and top coverage from the 62nd European Renal Association Congress.

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

Panelists discuss how the complexity of diagnosing C3 glomerulopathy (C3G), the need for long-term treatment options, and the importance of addressing unmet needs, including the psychological impact on patients and families, highlights the challenges and future directions in improving care for these individuals.

Panelists discuss how patient history, vaccination status, and risk of infection influence the decision to administer complement inhibitors, with some expressing caution in high-risk cases, particularly in pediatric populations with prior infections or low immunoglobulin levels.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

An analysis of the VALIANT trial provides insight into the benefits of pegcetacoplan in patients with C3G and IC-MPGN.

52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.

Panelists discuss how future clinical trials for C3 glomerulopathy (C3G) and other rare kidney diseases must evolve to accommodate emerging therapies targeting the complement system, improve inclusivity across patient populations, utilize molecular and genetic data, and reassess end point criteria to overcome challenges in patient recruitment and demonstrate treatment efficacy.

Panelists discuss how early protocol biopsies and proactive monitoring post-transplant can reveal subclinical recurrence of C3 glomerulopathy (C3G), prompting consideration of timely initiation of complement-targeting therapies to preserve graft function.

Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.